This announcement is a separate document:
Percheron Therapeutics Ltd: Topline Six-Month Results From Phase IIb Study of Avicursen
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.